Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label multicenter study of ALK-N001 in advanced gastrointestinal tumors
CTR20262971Phase 2Active
- Sponsor
- Zhejiang Anglikang Pharmaceutical
- Start
- Jul 2026
- Modality
- Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of QHL-1618 in gastrointestinal cancer, Esophageal Squamous Cell Carcinoma (ESCC), colorectal adenocarcinoma, sponsored by Zhejiang Anglikang Pharmaceutical. Started Jul 2026; status: active.
02
Drugs
QHL-1618
03
Conditions
gastrointestinal cancerEsophageal Squamous Cell Carcinoma (ESCC)colorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20262971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262971.